Next Article in Journal
Dent Disease Type 1: Still an Under-Recognized Renal Proximal Tubulopathy: A Case Report
Previous Article in Journal
Good Immunogenicity of Delayed Second Dose of BNT162b2 Vaccine in Individuals with Acute Allergic-like Reactions after the First Dose
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Reports
Volume 5
Issue 4
10.3390/reports5040049
reports-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Liver Transplantation from a Human Leukocyte Antigen-Matched Sibling Donor: Effectiveness of Direct-Acting Antiviral Therapy against Hepatitis C Virus Infection

by
Tatsuo Kanda
1,*,
Naoki Matsumoto
1,
Tomotaka Ishii
1,
Shuhei Arima
1,
Shinji Shibuya
1,
Masayuki Honda
1,
Reina Sasaki-Tanaka
1,
Ryota Masuzaki
1,
Shini Kanezawa
1,
Masahiro Ogawa
1,
Shintaro Yamazaki
2,
Osamu Aramaki
2,
Hirofumi Kogure
1 and
Yukiyasu Okamura
2
1
Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan
2
Division of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan
*
Author to whom correspondence should be addressed.
Reports 2022, 5(4), 49; https://doi.org/10.3390/reports5040049
Submission received: 5 November 2022 / Revised: 30 November 2022 / Accepted: 1 December 2022 / Published: 4 December 2022
Browse Figures
Versions Notes

Abstract

:
Through living-donor liver transplantation (LDLT) from a human leukocyte antigen (HLA)-matched sibling donor, it may be possible to stop the use of immunosuppressants. It is possible that acute antibody-mediated rejection and chronic active antibody-mediated rejection through the positivity of donor-specific anti-HLA antibodies and/or T cell-mediated rejection may affect the prognosis of liver transplantation. The etiologies of liver diseases of the recipient may also affect the post-transplantation course. Herein, we report on the successful re-treatment with direct-acting antiviral (DAA) therapy against hepatitis C virus (HCV) infection in a patient who underwent a LDLT from HLA-matched sibling donor. After liver transplantation for HCV-related liver diseases, it is easy for HCV to re-infect the graft liver under a lack of immunosuppressants. DAA therapy against HCV re-infection immediately after transplantation should be commenced, and it is important to eradicate HCV for better prognosis of the recipients in LDLT for HCV-related liver diseases.

1. Introduction

There have been several reports on successful liver transplantation from human leukocyte antigen (HLA)-matched sibling donors [1,2,3,4]. These reports discussed living-donor liver transplantation (LDLT) from human leukocyte antigen (HLA)-matched sibling donors, although long-term observations from these LDLT cases have not yet been reported. In general, identical HLA matching has enabled successful transplantation along with the stopping of immunosuppressants. These cases may bring useful knowledge for immunosuppressant withdrawal after liver transplantation.
In Japan, compared with other countries, due to the legal difficulties associated with cadaveric donation, LDLT is performed more often than brain death liver transplantation for end-stage liver diseases [5]. In Japan, chronic hepatitis C virus (HCV) infection is still one of the major etiologies of end-stage liver diseases [6,7]. It is unknown whether immunosuppressant-free liver transplantation has effects on HCV re-infection of the graft liver.
However, the liver diseases of recipients occasionally affect the clinical course after liver transplantation [8,9,10]. The development of antiviral therapies for hepatitis B virus (HBV) and HCV, respectively, could prevent the occurrence of complications accompanying HBV- and HCV-associated liver diseases, such as fibrosing cholestatic hepatitis. The development of direct-acting antivirals (DAAs) against HCV could lead to higher sustained virological response (SVR) rates with less adverse events, even in patients with liver transplantation, compared to interferon therapy, resulting in better survival [11,12,13].
Another problem is that recurrent autoimmune hepatitis (AIH) following liver transplant is frequent, as associated with some recipient features and/or the type of immunosuppressive medications used [14]. De novo donor-specific anti-HLA antibodies (dnDSAs) in pediatric liver transplant recipients have been associated with liver transplant rejection and liver fibrosis [15]. Donor-specific antibodies (DSAs) play a role in acute antibody-mediated rejection (AAMR) and chronic active antibody-mediated rejection (CAAMR) [16,17].
In this article, we present a case with liver transplant from HLA-matched sibling donor and successful re-treatment with DAA therapy against HCV infection, including follow-up with this patient up to about 8.5 years. We also discuss relevant topics.

2. Successful Re-Treatment with Direct-Acting Antiviral (DAA) Therapy against Hepatitis C Virus (HCV) Infection in a Patient Who Underwent a Living-Donor Liver Transplantation (LDLT) from a Human Leukocyte Antigen (HLA)-Matched Sibling Donor

2.1. Case

A man in his 40s underwent LDLT at our institution in 2014 for decompensated HCV-related cirrhosis. His height and weight were 170 cm and 69.9 kg, respectively. The organ donor was the patient’s identical older twin brother. The recipient’s diagnosis was HCV genotype (GT) 1b infection and decompensated cirrhosis. Before LDLT, the international normalized ratio was 1.38, platelet count 21,000/μL, albumin 2.3 g/dL, and total bilirubin 1.8 mg/dL. Child–Pugh score and grade were 8 and B, respectively. Model for end-stage liver disease (MELD) and MELD-Na scores were 11 and 12, respectively. α-fetoprotein and protein induced by vitamin K absence or antagonist-II (PIVKA-II) levels were 17.7 ng/mL and 33 mAU/mL, respectively. HCV RNA level was 6.5 LC/mL. HBV surface antigen and HBV DNA were negative and undetectable, although antibody to HBV core antigen was positive. His laboratory data and computed tomography (CT) images before liver transplantation are shown in Table 1 and Figure 1A, respectively.

2.2. Donor and Living-Donor Liver Transplantation (LDLT)

HLA matching (A24, A31; B52, B35; C3:03, C12:02; and DR 15, DR4) was identical between the two siblings. HLA-A, B, and DR types were determined by PCR-sequence based typing (SBT) and PCR-reverse sequence specific oligonucleotide (rSSO) methods, respectively, and HLA-C were established by PCR-SBT. These tests were performed by SRL (Hachioji, Tokyo, Japan). A direct test of mixed-donor lymphocyte cultures with recipient sera was judged as negative [1].
The explanted liver and spleen weight of this recipient were 728 g and 1090 g, respectively. The left lobe graft from older brother was 406 g, 33% of the recipient’s standard liver volume. The recipient underwent an uncomplicated LDLT, according to a previously described technique [18,19]. Intravenous methylprednisolone (600 mg) was administered intraoperatively. After post-operative day 7 (POD 7), the recipient received no immunosuppression. CT images right after liver transplantation are shown in Figure 1B.

2.3. Anti-HCV Therapies

After about 2 months post-transplantation, he was treated for his HCV with a 12-week combination of peginterferon α-2b (50–90 μg weekly), ribavirin (600 mg daily), and simeprevir (100 mg daily), followed by a 12-week combination of peginterferon α-2b and ribavirin [20]. HCV RNA was relapsed (7.2 LC/mL) after about 8 months of transplantation.
After 2 years of transplantation, he was retreated with a 12-week combination of sofosbuvir (400 mg daily) and ledipasvir (90 mg daily) [21]. Finally, he achieved SVR without HBV re-activation, although he had a history of HBV infection. Although almost 8.5 years have passed since transplantation, his HCV RNA and HBV DNA are now undetectable, and ultrasound sonography demonstrated no space occupying lesions and no advanced liver fibrosis (shear wave elastography, 5.64 kPa). His Child–Pugh score and grade were 5 and A, respectively (Table 2). The clinical course of this patient is shown in Figure 2.

3. Discussion

In the present report, we present about 8.5 years of follow-up of a patient who had undergone LDLT for HCV infection and decompensated cirrhosis from an HLA-matched sibling donor, and no immunosuppressants after POD 7. Notably, we found that HCV easily re-infected the graft liver without immunosuppressants.
After LDLT from an HLA-matched sibling donor, it may be possible to stop the use of immunosuppressants. Table 3 shows seven reported cases with LDLT from HLA-matched sibling donors. It has been reported that careful attention should be paid to DSA-positive cases in liver transplantation from an identical twin without immunosuppression [4], although, in our patient, DSA had not been examined yet. A negative cross-match was observed in our patients, although a positive cross-match in liver transplantation is associated with worse outcomes [22].
DSA to HLA have been associated with graft loss in hematopoietic progenitor cell transplantation [23]. The presence of mismatched antigens and epitopes might relate directly to the development of de novo DSA and rejection [24]. As seen in solid organ transplantation, the presence of DSA has been shown to be correlated with survival in recipients of hematopoietic stem cell transplants [25]. In general, development of anti-HLA antibodies may occur in certain patients receiving an HLA mismatched donor transplant. DSA-positive rate was significantly higher in the 90-day mortality group in LDLT. Post-operatively, the incidence of acute cellular rejection was higher in DSA-positive patients [26].
Antibody-mediated rejection (AMR) is relatively uncommon in ABO-compatible liver grafts, although antibody-mediated mechanisms may play a role in the differential pathogenesis of liver graft rejection [27]. Presence of DSA has been associated with inferior graft outcomes among certain liver transplant recipients [27,28,29]. In ABO-compatible liver transplantation, humoral alloreactivity mediated by DSA appears to be frequently associated with cellular mechanisms of rejection, as well as playing a role in ductopenia development [28]. Immune-mediated graft injury or a manifestation of chronic antibody-mediated rejection are also involved in graft hepatitis and liver fibrosis [29].
The etiologies of liver diseases in recipients affect the prognosis of post-liver transplantation. Recurrent AIH frequently occurs following liver transplantation, and is a major cause of allograft dysfunction, reduced graft, patient survival, and need for re-transplantation [14]. The probability of recurrent AIH is 20%, 31%, 37%, and 49% at 5, 10, 15, and 20 years, respectively [14]. AIH is characterized by a loss of immunological tolerance to hepatocytes [30]. CD4+CD25high Foxp3+ regulatory T cells (Tregs) cellular therapy could restore immune self-tolerance in AIH as well as benefit post-liver transplant patients by preventing graft rejection [30,31].
Immunosuppression is a major factor responsible for the accelerated recurrence of HCV infection [32]. Development of HCV-related fibrosis is accelerated after liver transplantation, which is influenced by several factors related to the virus, donor, recipient, surgery, and immunosuppression [33]. SVR alone can attenuate liver fibrosis in patients re-infected with HCV.
In the setting of liver transplantation, prevention of cytomegalovirus (CMV) infection and control of CMV replication by pre-existing natural adaptive immunity is minimally influenced by HLA-matching of the donor and recipient [34]. Host HLA class I and HLA class II determinants play a role in the lysis of Epstein–Barr virus-infected allogeneic host cells by cytotoxic T cells [35]. Several HLA polymorphisms have been associated with HCV clearance or persistence [36,37,38]. The negative effects of HCV on antigen-presenting cell function could lead to reduced immunogenicity in vivo [39]. HCV plays an inhibitory role in cathepsin S-mediated MHC class II maturation, which may contribute to the weak immunogenicity of HCV antigens in patients with chronic HCV infection [40]. Interestingly, the present case also demonstrated that, without immunosuppression, HCV may easily re-infect the graft liver, although very rapid steroid withdrawal was performed.
The present case received a 12-week combination of peginterferon α-2b (50–90 μg weekly) and ribavirin (600 mg daily), followed by a 12-week combination of peginterferon α-2b, ribavirin, and simeprevir (100 mg daily) to combat HCV re-infection immediately after transplantation; however, HCV RNA relapsed after the stoppage of these combination therapies. The dose of interferon seemed less than the standard of care in the first anti-HCV therapy. We did not use a higher dose due to the adverse events of interferon. Although resistance-associated substitutions in the HCV NS3/4A region also appeared (Figure 2), SVR was achieved after the 12-week combination of sofosbuvir (400 mg daily) and ledipasvir (90 mg daily) at 2 years after liver transplantation, and his post-operative process is currently going well at about 8.5 years. Thus, interferon-free DAA treatment may be useful for the achievement of SVR. DAA should be started as soon as possible following liver transplantation in HCV-infected patients who receive the graft from an identical twin without immunosuppression.
When HCV was eradicated in these HBsAg-positive patients or patients with previous HBV infection (anti-HBc and/or anti-HBs-positive), it was shown that HBV reactivation or HBV DNA reappearance was observed in 41% or 0.9%, respectively [41]. In the present case, HBV DNA reappearance was not observed after the eradication of HCV RNA.
In general, minimal listing criteria for elective liver transplantation for HCV-related end stage liver diseases are similar to other causes of chronic liver failure. Although HCV causes cirrhosis, HCC and chronic liver failure, diuretic-resistant ascites or hydrothorax, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatopulmonary syndrome, intractable encephalopathy, and small HCC may occur before liver transplantation [42]. Li et al. favoured DAA therapy before liver transplant in patients with MELD scores < 18 and DAA therapy post-liver transplant in MELD scores > 20 [43]. HCV infection is a risk for intraoperative pulmonary embolism or intracardiac thrombus formation in patients with liver transplantation [44].
In transplant candidates with positive serum HCV RNA prior to transplant, recurrent HCV infection of the allograft occurs following liver transplantation [42]. Most patients will develop acute hepatitis C at 4–12 weeks post-transplant. A small number of patients (2–5%) develop severe cholestatic hepatitis, characterized by extremely high levels of HCV RNA, and severe cholestasis, often causing their death [42].
As recurrent HCV infection with accelerated progression to cirrhosis of the graft is a frequent cause of graft loss and the need for retransplantation, better pre- and/or post-transplant antiviral therapy is needed [45]. Improving the outcome of recurrent HCV infection may also be achieved by reducing overall immunosuppression [46].
Concerning the weaning of immunosuppression, a complete withdrawal of immunosuppression may be achieved in selected liver transplantation-recipients [47,48]. Although drug-induced suppression of the immune system is essential in preventing graft rejection, it has been well-established that it is also associated with oncogenesis [48]. Although the mechanism of graft acceptance in these patients is yet to be elucidated, we believe that no HLA-mismatch, DSA, and T cell-mediated rejection may be important for successful LDLT without immunosuppressants.

4. Conclusions

We reported on about 8.5 years of follow up in a patient who had undergone liver transplantation from an identical twin without immunosuppression. Although it is no doubt that direct viral inhibition should be started as soon as logistically possible following transplant, we herein reinforce those results in living donors who have had minimal immunosuppression.

Author Contributions

Conceptualization, T.K.; formal analysis, T.K.; data curation, T.K.; writing—original draft preparation, T.K.; writing—review and editing, T.K., N.M., T.I., S.A., S.S., M.H., R.S.-T., R.M., S.K., M.O., S.Y., O.A., H.K. and Y.O.; supervision, H.K., S.Y., O.A. and Y.O.; project administration, T.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Ethical approval was not sought for the present study because of a case report.

Informed Consent Statement

Written informed consent has been obtained from the patient to publish this paper.

Data Availability Statement

The data underlying this article are available in this article.

Acknowledgments

The authors thank Mitsuhiko Moriyama and Tadatoshi Takayama, Nihon University School of Medicine, for valuable discussions.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Sugawara, Y.; Ohtsuka, H.; Kaneko, J.; Ohkubo, T.; Imamura, H.; Makuuchi, M. Successful treatment of hepatitis C virus after liver transplantation from an identical twin. Transplantation 2002, 73, 1850–1851. [Google Scholar] [CrossRef] [PubMed]
  2. Liu, L.U.; Schiano, T.D.; Min, A.D.; Kim-Schluger, L.; Schwartz, M.E.; Emre, S.; Fishbein, T.M.; Bodenheimer, H.C., Jr.; Miller, C.M. Syngeneic living-donor liver transplantation without the use of immunosuppression. Gastroenterology 2002, 123, 1341–1345. [Google Scholar] [CrossRef] [PubMed]
  3. Yoshizawa, A.; Takada, Y.; Fujimoto, Y.; Koshiba, T.; Haga, H.; Nabeshima, S.; Uemoto, S. Liver transplantation from an identical twin without immunosuppression, with early recurrence of hepatitis C. Am. J. Transplant. 2006, 6, 2812–2816. [Google Scholar] [CrossRef] [PubMed]
  4. Toshida, K.; Toshima, T.; Yoshizumi, T.; Harada, N.; Itoh, S.; Nagao, Y.; Wang, H.; Shimagaki, T.; Kurihara, T.; Mori, M. Immunosuppression Free Protocol for Liver Transplant from an Identical Twin Mimicking Positive Donor-Specific Antibodies: A Case Report. Transplant. Proc. 2021, 53, 2576–2579. [Google Scholar] [CrossRef] [PubMed]
  5. Kanda, T.; Yokosuka, O.; Ehata, T.; Maru, Y.; Imazeki, F.; Saisho, H.; Shiratori, Y.; Omata, M. Detection of GBV-C RNA in patients with non-A-E fulminant hepatitis by reverse-transcription polymerase chain reaction. Hepatology 1997, 25, 1261–1265. [Google Scholar] [CrossRef]
  6. Enomoto, H.; Ueno, Y.; Hiasa, Y.; Nishikawa, H.; Hige, S.; Takikawa, Y.; Taniai, M.; Ishikawa, T.; Yasui, K.; Takaki, A.; et al. Transition in the etiology of liver cirrhosis in Japan: A nationwide survey. J. Gastroenterol. 2020, 55, 353–362. [Google Scholar] [CrossRef] [Green Version]
  7. Enomoto, H.; Ueno, Y.; Hiasa, Y.; Nishikawa, H.; Hige, S.; Takikawa, Y.; Taniai, M.; Ishikawa, T.; Yasui, K.; Takaki, A.; et al. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J. Gastroenterol. 2021, 56, 158–167. [Google Scholar] [CrossRef]
  8. O’Grady, J.G.; Smith, H.M.; Davies, S.E.; Daniels, H.M.; Donaldson, P.T.; Tan, K.C.; Portmann, B.; Alexander, G.J.; Williams, R. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J. Hepatol. 1992, 14, 104–111. [Google Scholar] [CrossRef]
  9. Taga, S.A.; Washington, M.K.; Terrault, N.; Wright, T.L.; Somberg, K.A.; Ferrell, L.D. Cholestatic hepatitis C in liver allografts. Liver Transpl. Surg. 1998, 4, 304–310. [Google Scholar] [CrossRef] [Green Version]
  10. Shin, E.; Kim, J.H.; Yu, E. Histopathological causes of late liver allograft dysfunction: Analysis at a single institution. Korean J. Pathol. 2013, 47, 21–27. [Google Scholar] [CrossRef]
  11. Sasaki, R.; Kanda, T.; Ohtsuka, M.; Yasui, S.; Haga, Y.; Nakamura, M.; Yokoyama, M.; Wu, S.; Nakamoto, S.; Arai, M.; et al. Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Rep. Gastroenterol. 2016, 10, 366–372. [Google Scholar] [CrossRef] [PubMed]
  12. Ueda, Y.; Kobayashi, T.; Ikegami, T.; Miuma, S.; Mizuno, S.; Akamatsu, N.; Takaki, A.; Ishigami, M.; Takatsuki, M.; Sugawara, Y.; et al. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: A Japanese multicenter experience. J. Gastroenterol. 2019, 54, 660–666. [Google Scholar] [CrossRef] [PubMed]
  13. Jacob, J.S.; Shaikh, A.; Goli, K.; Rich, N.E.; Benhammou, J.N.; Ahmed, A.; Kim, D.; Rana, A.; Goss, J.A.; Naggie, S.; et al. Improved Survival after Liver Transplantation for Patients with HIV and HIV/HCV Coinfection in the INSTI and DAA eras. J. Clin. Infect. Dis. 2022, ciac821. [Google Scholar] [CrossRef] [PubMed]
  14. Montano-Loza, A.J.; Ronca, V.; Ebadi, M.; Hansen, B.E.; Hirschfield, G.; Elwir, S.; Alsaed, M.; Milkiewicz, P.; Janik, M.K.; Marschall, H.U.; et al. Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. J. Hepatol. 2022, 77, 84–97. [Google Scholar] [CrossRef] [PubMed]
  15. Liu, W.; Wang, Z.L.; Kang, Z.Y.; Xiao, Y.L.; Liu, C.; Li, D.H. Liver graft injury caused by de novo donor-specific HLA antibodies in pediatric liver transplant recipients with low, moderate, and high immunologic risk. Am. J. Surg. 2022; online ahead of print. [Google Scholar] [CrossRef]
  16. Del Bello, A.; Danjoux, M.; Congy-Jolivet, N.; Lavayssière, L.; Esposito, L.; Muscari, F.; Kamar, N. Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation. J. Gastroenterol. Hepatol. 2017, 32, 887–893. [Google Scholar] [CrossRef]
  17. Uebayashi, E.Y.; Okajima, H.; Yamamoto, M.; Ogawa, E.; Okamoto, T.; Haga, H.; Hatano, E. The New Challenge in Pediatric Liver Transplantation: Chronic Antibody-Mediated Rejection. J. Clin. Med. 2022, 11, 4834. [Google Scholar] [CrossRef]
  18. Kanda, T.; Yokosuka, O.; Fujiwara, K.; Saisho, H.; Shiga, H.; Oda, S.; Okuda, K.; Sugawara, Y.; Makuuchi, M.; Hirasawa, H. Fulminant hepatic failure associated with triazolam. Dig. Dis. Sci. 2002, 47, 1111–1114. [Google Scholar] [CrossRef]
  19. Sugawara, Y.; Makuuchi, M. Living donor liver transplantation: Present status and recent advances. Br. Med. Bull. 2006, 75–76, 15–28. [Google Scholar] [CrossRef] [Green Version]
  20. Kanda, T.; Nakamoto, S.; Sasaki, R.; Nakamura, M.; Yasui, S.; Haga, Y.; Ogasawara, S.; Tawada, A.; Arai, M.; Mikami, S.; et al. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. Int. J. Med. Sci. 2016, 13, 310–315. [Google Scholar] [CrossRef]
  21. Korenaga, M.; Murata, K.; Izumi, N.; Tamaki, N.; Yokosuka, O.; Takehara, T.; Sakamoto, N.; Suda, G.; Nishiguchi, S.; Enomoto, H.; et al. No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy. Glob. Health Med. 2022, 4, 216–224. [Google Scholar] [CrossRef] [PubMed]
  22. Kubal, C.A.; Mangus, R.S.; Saxena, R.; Lobashevsky, A.; Higgins, N.; Agarwal, A.; Fridell, J.A.; Tector, A.J. Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction. Transplantation 2014, 97, 56–63. [Google Scholar] [CrossRef] [PubMed]
  23. Hassan, S.; West, K.A.; Ward, W.W.; Kanakry, J.A.; Flegel, W.A. Rebound and overshoot of donor-specific antibodies to human leukocyte antigens (HLA) during desensitization with plasma exchanges in hematopoietic progenitor cell transplantation: A case report. Transfusion 2021, 61, 1980–1986. [Google Scholar] [CrossRef] [PubMed]
  24. Trentadue, G.; Dijkstra, G. Current understanding of alloimmunity of the intestinal graft. Curr. Opin. Organ Transplant. 2015, 20, 286–294. [Google Scholar] [CrossRef] [PubMed]
  25. Ciurea, S.O.; Cao, K.; Fernandez-Vina, M.; Kongtim, P.; Malki, M.A.; Fuchs, E.; Luznik, L.; Huang, X.J.; Ciceri, F.; Locatelli, F.; et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2018, 53, 521–534. [Google Scholar] [CrossRef] [Green Version]
  26. Tamura, K.; Tohyama, T.; Watanabe, J.; Nakamura, T.; Ueno, Y.; Inoue, H.; Honjo, M.; Sakamoto, K.; Takai, A.; Ogawa, K.; et al. Preformed donor-specific antibodies are associated with 90-day mortality in living-donor liver transplantation. Hepatol. Res. 2019, 49, 929–941. [Google Scholar] [CrossRef]
  27. Muro, M.; Moya-Quiles, M.R.; Mrowiec, A. Humoral Response in Liver Allograft Transplantation: A Review of the Role of Anti-Human Leukocyte Antigen (HLA) Antibodies. Curr. Protein Pept. Sci. 2016, 17, 776–784. [Google Scholar] [CrossRef]
  28. Musat, A.I.; Agni, R.M.; Wai, P.Y.; Pirsch, J.D.; Lorentzen, D.F.; Powell, A.; Leverson, G.E.; Bellingham, J.M.; Fernandez, L.A.; Foley, D.P.; et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am. J. Transplant. 2011, 11, 500–510. [Google Scholar] [CrossRef] [Green Version]
  29. Kelly, D.; Verkade, H.J.; Rajanayagam, J.; McKiernan, P.; Mazariegos, G.; Hübscher, S. Late graft hepatitis and fibrosis in pediatric liver allograft recipients: Current concepts and future developments. Liver Transpl. 2016, 22, 1593–1602. [Google Scholar] [CrossRef]
  30. Oo, Y.H.; Sakaguchi, S. Regulatory T-cell directed therapies in liver diseases. J. Hepatol. 2013, 59, 1127–1134. [Google Scholar] [CrossRef]
  31. Sagoo, P.; Ali, N.; Garg, G.; Nestle, F.O.; Lechler, R.I.; Lombardi, G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci. Transl. Med. 2011, 3, 83ra42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Samonakis, D.N.; Germani, G.; Burroughs, A.K. Immunosuppression and HCV recurrence after liver transplantation. J. Hepatol. 2012, 56, 973–983. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Joshi, D.; Pinzani, M.; Carey, I.; Agarwal, K. Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 710–721. [Google Scholar] [CrossRef] [PubMed]
  34. Aldridge, R.W.; Mattes, F.M.; Rolando, N.; Rolles, K.; Smith, C.; Shirling, G.; Atkinson, C.; Burroughs, A.K.; Milne, R.S.; Emery, V.C.; et al. Effects of donor/recipient human leukocyte antigen mismatch on human cytomegalovirus replication following liver transplantation. Transpl. Infect. Dis. 2015, 17, 25–32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Plotnicky, H.; Touraine, J.L. Cytotoxic T cells from a human chimera induce regression of Epstein-Barr virus-infected allogeneic host cells. Int. Immunol. 1993, 5, 1413–1420. [Google Scholar] [CrossRef] [PubMed]
  36. Höhler, T.; Gerken, G.; Notghi, A.; Knolle, P.; Lubjuhn, R.; Taheri, H.; Schneider, P.M.; Meyer zum Büschenfelde, K.H.; Rittner, C. MHC class II genes influence the susceptibility to chronic active hepatitis C. J. Hepatol. 1997, 27, 259–264. [Google Scholar] [CrossRef] [PubMed]
  37. Minton, E.J.; Smillie, D.; Neal, K.R.; Irving, W.L.; Underwood, J.C.; James, V. Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J. Infect. Dis. 1998, 178, 39–44. [Google Scholar] [CrossRef] [PubMed]
  38. McKiernan, S.M.; Hagan, R.; Curry, M.; McDonald, G.S.; Nolan, N.; Crowley, J.; Hegarty, J.; Lawlor, E.; Kelleher, D. The MHC is a major determinant of viral status, but not fibrotic stage, in individuals infected with hepatitis C. Gastroenterology 2000, 118, 1124–1130. [Google Scholar] [CrossRef]
  39. Saito, K.; Ait-Goughoulte, M.; Truscott, S.M.; Meyer, K.; Blazevic, A.; Abate, G.; Ray, R.B.; Hoft, D.F.; Ray, R. Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J. Virol. 2008, 82, 3320–3328. [Google Scholar] [CrossRef] [Green Version]
  40. Kim, H.; Mazumdar, B.; Bose, S.K.; Meyer, K.; Di Bisceglie, A.M.; Hoft, D.F.; Ray, R. Hepatitis C virus-mediated inhibition of cathepsin S increases invariant-chain expression on hepatocyte surface. J. Virol. 2012, 86, 9919–9928. [Google Scholar] [CrossRef]
  41. Kanda, T.; Lau, G.K.K.; Wei, L.; Moriyama, M.; Yu, M.L.; Chuang, W.L.; Ibrahim, A.; Lesmana, C.R.A.; Sollano, J.; Kumar, M.; et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol. Int. 2019, 13, 649–661. [Google Scholar] [CrossRef] [Green Version]
  42. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party; McCaughan, G.W.; Omata, M.; Amarapurkar, D.; Bowden, S.; Chow, W.C.; Chutaputti, A.; Dore, G.; Gane, E.; Guan, R.; et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J. Gastroenterol. Hepatol. 2007, 22, 615–633. [Google Scholar] [CrossRef]
  43. Li, J.; Wu, V.; Pan, C.Q. Direct antiviral therapy for hepatitis C cirrhotic patients in liver transplantation settings: A systematic review. Hepatol. Int. 2022, 16, 1020–1031. [Google Scholar] [CrossRef] [PubMed]
  44. Warnaar, N.; Molenaar, I.Q.; Colquhoun, S.D.; Slooff, M.J.; Sherwani, S.; de Wolf, A.M.; Porte, R.J. Intraoperative pulmonary embolism and intracardiac thrombosis complicating liver transplantation: A systematic review. J. Thromb. Haemost. 2008, 6, 297–302. [Google Scholar] [CrossRef] [PubMed]
  45. Brown, R.S. Hepatitis C and liver transplantation. Nature 2005, 436, 973–978. [Google Scholar] [CrossRef] [PubMed]
  46. Berenguer, M.; Aguilera, V.; Prieto, M.; San Juan, F.; Rayón, J.M.; Benlloch, S.; Berenguer, J. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J. Hepatol. 2006, 44, 717–722. [Google Scholar] [CrossRef]
  47. Takatsuki, M.; Uemoto, S.; Inomata, Y.; Egawa, H.; Kiuchi, T.; Fujita, S.; Hayashi, M.; Kanematsu, T.; Tanaka, K. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001, 72, 449–454. [Google Scholar] [CrossRef]
  48. Angelico, R.; Parente, A.; Manzia, T.M. Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: A compromise between the risk of recurrence and the risk of rejection? Transl. Gastroenterol. Hepatol. 2017, 2, 74. [Google Scholar] [CrossRef]
Reports 05 00049 g001 550
Figure 1. Computed tomography images before and after living-donor liver transplantation (LDLT): (A) before LDLT; (B) right after LDLT; and (C) present (about 8.5 years post-LDLT).
Figure 1. Computed tomography images before and after living-donor liver transplantation (LDLT): (A) before LDLT; (B) right after LDLT; and (C) present (about 8.5 years post-LDLT).
Reports 05 00049 g001
Reports 05 00049 g002 550
Figure 2. Clinical course of the patient. RASs, resistance-associated substitutions; Neg, undetectable HCV RNA; PegIFN, peginterferon α-2b; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; LDV, ledipasvir; ALT, alanine transaminase.
Figure 2. Clinical course of the patient. RASs, resistance-associated substitutions; Neg, undetectable HCV RNA; PegIFN, peginterferon α-2b; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; LDV, ledipasvir; ALT, alanine transaminase.
Reports 05 00049 g002
Table
Table 1. Laboratory data of recipient before living-donor liver transplantation (LDLT).
Table 1. Laboratory data of recipient before living-donor liver transplantation (LDLT).
ItemValuesItemValuesItemValues
WBC2000/μLTP5.1 g/dLHBsAgNegative
RBC2,500,000/μLAlbumin2.3 g/dLAnti-HBsNegative
Hemoglobin8.5 g/dLT.CHO117 mg/dLAnti-HBcPositive
Hematocrit26.1%TG34 mg/dLHBV DNAUndetectable
Platelets21,000/μLBUN8.6 mg/dLAnti-HCVPositive
PT59%Creatinine0.95 mg/dLHCV RNA6.5 LC/mL
PT-INR1.38CK49 IU/LHCV GTGT1b
AST63 IU/LAmylase39 IU/LAnti-HIVNegative
ALT30 IU/LBS87 mg/dLIgG2250 mg/dL
LDH187 IU/LHbA1c3.9%IgA191 mg/dL
γ-GTP20 IU/LNH354 μg/dLIgM98 mg/dL
ALP231 IU/LCRP<0.10 mg/dLANANegative
T. Bil1.8 mg/dLAFP17.7 ng/mLAMAM2Negative
D. Bil1.0 mg/dLPIVKA-II33 mAU/mLAnti-LKM1Negative
WBC, white blood cell count; RBC, red blood cell count; PT, prothrombin time; PT-INR, PT international normalized ratio; AST, aspartate aminotransferase; ALT, alanine transaminase; LDH, lactate dehydrogenase; γ-GTP, γ-glutamyltransferase; ALP, alkaline phosphatase; T. Bil, total bilirubin; D. Bil, direct bilirubin; TP, total protein; T.CHO, total cholesterol; TG, triglyceride; BUN, blood urea nitrogen; CK, creatine kinase; BS, blood sugar; HbA1c, hemoglobin A1c; NH3, ammonia; CRP, C-reactive protein; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; HBsAg, hepatitis B virus (HBV) surface antigen; anti-HBs, anti-HBV surface antibody; anti-HBc, anti-HBV core antibody; anti-HCV, anti-hepatitis C virus (HCV) antibody; HCV GT, HCV genotype; anti-HIV, anti-human immunodeficiency virus antibody; Ig, immunoglobulin; ANA, anti-nuclear antibody; AMAM2, anti-mitochondrial M2 antibody; anti-LKM1, anti-liver/kidney microsome type 1 antibody.
Table
Table 2. Laboratory data of recipient about 8.5 years after living-donor liver transplantation (LDLT).
Table 2. Laboratory data of recipient about 8.5 years after living-donor liver transplantation (LDLT).
ItemValuesItemValuesItemValues
WBC7000 /μLT. Bil0.5 mg/dLAFP17.7 ng/mL
RBC4,150,000 /μLD. Bil0.1 mg/dLPIVKA-II33 mAU/mL
Hemoglobin12.6 g/dLTP7.0 g/dLHBsAgNegative
Hematocrit40.3%Albumin3.9 g/dLAnti-HBsPositive
Platelets276,000/μLT.CHO235 mg/dLAnti-HBcPositive
PT100%TG85 mg/dLHBV DNAUndetectable
PT-INR0.95BUN11.3 mg/dLAnti-HCVPositive
AST19 IU/LCreatinine0.76 mg/dLHCV RNAUndetectable
ALT16 IU/LCK85 IU/LAnti-HIVNegative
LDH181 IU/LBS92 mg/dL
γ-GTP43 IU/LHbA1c5.4%
ALP244 IU/L
WBC, white blood cell count; RBC, red blood cell count; PT, prothrombin time; PT-INR, PT international normalized ratio; AST, aspartate aminotransferase; ALT, alanine transaminase; LDH, lactate dehydrogenase; γ-GTP, γ-glutamyltransferase; ALP, alkaline phosphatase; T. Bil, total bilirubin; D. Bil, direct bilirubin; TP, total protein; T.CHO, total cholesterol; TG, triglyceride; BUN, blood urea nitrogen; CK, creatine kinase; BS, blood sugar; HbA1c, hemoglobin A1c; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; HBsAg, hepatitis B virus (HBV) surface antigen; anti-HBs, anti-HBV surface antibody; anti-HBc, anti-HBV core antibody; anti-HCV, anti-hepatitis C virus (HCV) antibody; anti-HIV, anti-human immunodeficiency virus antibody.
Table
Table 3. Seven reported cases with living-donor liver transplantation from human leukocyte antigen-matched sibling donors.
Table 3. Seven reported cases with living-donor liver transplantation from human leukocyte antigen-matched sibling donors.
CaseAge (Years)/GenderDisease(s) of RecipientsGraftImmunosuppression (Duration)
149/MaleHCV cirrhosisRight lateral sector from brothermPSL (POD 0–30)
243/FemaleHBV cirrhosis and HCCRight lobe from brotherNone
356/FemaleNeuroendocrine tumor metastasis to the liverRight lobe from sisterNone
451/MaleHCV cirrhosis and HCCRight lobeNone
538/MaleHCV cirrhosisRight lobeNone
6In his 40′s/MaleHCV cirrhosisLeft lobe from older brothermPSL (POD 0–5)
757/MaleAcute liver failureRight lobe from younger brotherFK/PSL (post operative 0–7 months)
CaseRejectionFollow-Up Period (years)Others: HCV GTs and Post-Transplantation TherapeusisReference
1NoAbout 1HCV GT1b; Mixed lymphocyte cultures, negative; Interferon α 2a plus ribavirin, SVR[1]
2NoAbout 1Lamivudine along with monthly hepatitis B immune globulin infusions[2]
3NoAbout 0.5Sandostatin (Novartis, Switzerland) and interferon[2]
4NoAbout 1.5HCV GT1b; Interferon α plus ribavirin, SVR[3]
5NoAbout 0.5HCV GT1b; Interferon α plus ribavirin[3]
6NoAbout 8.5Mixed lymphocyte cultures, negative; simeprevir/peginterferon α/ribavirin; sofosbuvir /ledipasvir, SVROur case
7NoAbout 0.5DSA, positive (Class II ≥ 2000 MFI).[4]
HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; mPSL, methylprednisolone; FK, tacrolimus; POD, post-operative day; GT, genotype; SVR, sustained virological response; DSA, donor-specific antibody.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kanda, T.; Matsumoto, N.; Ishii, T.; Arima, S.; Shibuya, S.; Honda, M.; Sasaki-Tanaka, R.; Masuzaki, R.; Kanezawa, S.; Ogawa, M.; et al. Liver Transplantation from a Human Leukocyte Antigen-Matched Sibling Donor: Effectiveness of Direct-Acting Antiviral Therapy against Hepatitis C Virus Infection. Reports 2022, 5, 49. https://doi.org/10.3390/reports5040049

AMA Style

Kanda T, Matsumoto N, Ishii T, Arima S, Shibuya S, Honda M, Sasaki-Tanaka R, Masuzaki R, Kanezawa S, Ogawa M, et al. Liver Transplantation from a Human Leukocyte Antigen-Matched Sibling Donor: Effectiveness of Direct-Acting Antiviral Therapy against Hepatitis C Virus Infection. Reports. 2022; 5(4):49. https://doi.org/10.3390/reports5040049

Chicago/Turabian Style

Kanda, Tatsuo, Naoki Matsumoto, Tomotaka Ishii, Shuhei Arima, Shinji Shibuya, Masayuki Honda, Reina Sasaki-Tanaka, Ryota Masuzaki, Shini Kanezawa, Masahiro Ogawa, and et al. 2022. "Liver Transplantation from a Human Leukocyte Antigen-Matched Sibling Donor: Effectiveness of Direct-Acting Antiviral Therapy against Hepatitis C Virus Infection" Reports 5, no. 4: 49. https://doi.org/10.3390/reports5040049

Article Metrics

Back to TopTop